Cargando…
A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
BACKGROUND: Denosumab entered the Chinese market for the first time in 2020. Since it is a short period of time, there is a lack of data on its effectiveness and safety in Chinese people. The objective of this study was to evaluate the effectiveness and safety of denosumab in delaying skeletal-relat...
Autores principales: | Li, Wei, Wu, Xinyu, Yu, Heng, Zhu, Zekai, Li, Wenjie, Huang, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336762/ https://www.ncbi.nlm.nih.gov/pubmed/37448470 http://dx.doi.org/10.1177/11795549231182266 |
Ejemplares similares
-
Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012) -
Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012) -
Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
por: Mizuta, Kohei, et al.
Publicado: (2023) -
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023) -
Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report
por: Wang, Guannan, et al.
Publicado: (2019)